HDM2006 / Huadong Medicine - LARVOL DELTA

HDM2006, A novel and potent HPK1 PROTAC, enhances immune cell activation and induces robust tumor growth inhibition (AACR 2025) - "HDM2006 is a novel, potent, highly selective and orally active PROTAC targeting HPK1. Preclinical studies have confirmed that HDM2006 has excellent profile for druggability, safety, and efficacy. HDM2006 has entered the clinical Phase 1 trial."

Immune cell • Colorectal Cancer • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • CRBN • IFNG

A Study of HDM2006 in Patients With Advanced Solid Tumor (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

First-in-human • Monotherapy • New P1 trial • Head and Neck Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck